These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27899043)

  • 1. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
    Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.
    Fernández-Lázaro D; Iglesias-Lázaro M; Garrosa E; Rodríguez-García S; Jerves Donoso D; Gutiérrez-Abejón E; Jorge-Finnigan C
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
    Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
    Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contemporary management of systemic sclerosis.
    Eldoma M; Pope J
    Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
    Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
    Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is biological therapy in systemic sclerosis the answer?
    Misra DP; Ahmed S; Agarwal V
    Rheumatol Int; 2020 May; 40(5):679-694. PubMed ID: 31960079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 15. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
    Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH
    Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.
    Ntelis K; Solomou EE; Sakkas L; Liossis SN; Daoussis D
    Semin Arthritis Rheum; 2017 Dec; 47(3):409-417. PubMed ID: 28602360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
    Sakkas LI
    Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.